# Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

> **NCT00729183** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 214 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Odanacatib
- **DRUG:** Placebo
- **DRUG:** Vitamin D3
- **DRUG:** Calcium supplement

## Key facts

- **NCT ID:** NCT00729183
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-02
- **Primary completion:** 2010-03-23
- **Final completion:** 2011-03-21
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729183, "Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00729183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*